Click on the “Search Now” button to search for research studies enrolling people like you. Need help getting started? Click on “Tips for Searching Studies” to find resources and assistance to help you find studies.
Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib
Clinicaltrials.gov identifier:
NCT03337087
Treatment:
Colorectal, Pancreatic
Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations
Clinicaltrials.gov identifier:
NCT02286687
Treatment:
Breast, Ovarian, Pancreatic, Prostate
TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency
Clinicaltrials.gov identifier:
NCT03395197
Treatment:
Prostate
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment:
Colorectal, Endometrial, Pancreatic
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)
Clinicaltrials.gov identifier:
NCT03043313
Treatment:
Colorectal
Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome
Clinicaltrials.gov identifier:
NCT04379999
Prevention:
Colorectal
Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
Clinicaltrials.gov identifier:
NCT03685331
Treatment:
Breast
Men at High Genetic Risk for Prostate Cancer
Clinicaltrials.gov identifier:
NCT03805919
Prevention:
Prostate
Blood Markers of Early Pancreas Cancer
Clinicaltrials.gov identifier:
NCT03568630
Prevention:
Pancreatic
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
Clinicaltrials.gov identifier:
NCT04251052
Prevention:
Ovarian
Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab
Clinicaltrials.gov identifier:
NCT04493060
Treatment:
Pancreatic
AMPLIFY: a new online weight loss study specifically for cancer survivors!
Clinicaltrials.gov identifier:
NCT04000880
Quality of Life:
Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor
Developing a Test for the Detection of Ovarian Cancer
Clinicaltrials.gov identifier:
NCT04794322
Prevention:
Ovarian
Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)
Clinicaltrials.gov identifier:
NCT02997228
Treatment:
Colorectal
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
Clinicaltrials.gov identifier:
NCT04191135
Treatment:
Breast
TALAVE: Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Clinicaltrials.gov identifier:
NCT03964532
Treatment:
Breast
Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation
Clinicaltrials.gov identifier:
NCT02478892
Prevention:
Pancreatic
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
Clinicaltrials.gov identifier:
NCT03831698
Prevention:
Colorectal
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment:
Pancreatic
Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations
Prevention:
Breast, Ovarian, Pancreatic, Prostate
Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT04115306
Treatment:
Breast
Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer
Clinicaltrials.gov identifier:
NCT04214067
Treatment:
Endometrial
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Clinicaltrials.gov identifier:
NCT04042831
Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)
Clinicaltrials.gov identifier:
NCT04008030
Treatment:
Colorectal
A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People with Advanced Pancreatic Cancer and BRCA Mutations
Clinicaltrials.gov identifier:
NCT04150042
Treatment:
Pancreatic
Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
Clinicaltrials.gov identifier:
NCT04666740
Treatment:
Pancreatic
Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors
Clinicaltrials.gov identifier:
NCT03581357
Quality of Life:
Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor, Pancreatic Cancer Survivor
Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)
Clinicaltrials.gov identifier:
NCT03404960
Treatment:
Pancreatic
Mobile Mindfulness Meditation Intervention for Cancer Survivors
Clinicaltrials.gov identifier:
NCT03581357
Quality of Life:
Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor, Pancreatic Cancer Survivor
TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer
Clinicaltrials.gov identifier:
NCT02975934
Treatment:
Prostate
Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT0823654
Quality of Life:
High Risk But No Cancer, Breast Cancer Survivor
Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations
Clinicaltrials.gov identifier:
NCT03344965
Treatment:
Breast
PARP Inhibitor for Metastatic Prostate Cancer With DNA Repair Defects
Clinicaltrials.gov identifier:
NCT03012321
Treatment:
Prostate
Studying a Combination of Immunotherapies and Biomarker for Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT03668119
Treatment:
Breast, Ovarian, Pancreatic, Prostate, Colorectal, Endometrial
Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations
Clinicaltrials.gov identifier:
NCT03990896
Treatment:
Breast
A Study of Nivolumab in Selected Uterine Cancer Patients
Clinicaltrials.gov identifier:
NCT03241745
Treatment:
Endometrial
PARP Inhibitor Alone or Plus Immunotherapy for Advanced BRCA-Associated Breast Cancer
Clinicaltrials.gov identifier:
NCT02849496
Treatment:
Breast
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients (E-Reach)
Clinicaltrials.gov identifier:
NCT04353973
Treatment:
Breast, Ovarian, Pancreatic, Prostate
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Clinicaltrials.gov identifier:
NCT02912559
Treatment:
Colorectal
Genetic Testing for Men with Metastatic Prostate Cancer (GENTleMEN Study)
Clinicaltrials.gov identifier:
NCT03503097
Treatment:
Prostate
Genetic Education for Men (GEM Study)
Clinicaltrials.gov identifier:
NCT02957981
Prevention:
Prostate
Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth
Clinicaltrials.gov identifier:
NCT03327103
Treatment:
Prostate
Quality of Life:
Prostate Cancer Survivor
Pancreatic Cancer Screening Study for High Risk People
Clinicaltrials.gov identifier:
NCT03250078
Prevention:
Pancreatic
Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
Clinicaltrials.gov identifier:
NCT04067726
Prevention:
Breast
Study of Safety and Effectiveness of Motiva® Breast Implants
Clinicaltrials.gov identifier:
NCT03579901
Quality of Life:
High Risk But No Cancer, Breast Cancer Survivor
Study for People with Unexpected Genetic Results
Clinicaltrials.gov identifier:
NCT02595957
Prevention:
Breast, Ovarian, Pancreatic, Prostate
A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes
Clinicaltrials.gov identifier:
NCT04171700
Treatment:
Breast, Ovarian, Pancreatic, Prostate, Endometrial
.jpg?h=300&w=400&fit=contain)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
Clinicaltrials.gov identifier:
NCT03572374
Quality of Life:
Breast Cancer Survivor
ELLIE's Project
Quality of Life:
High Risk But No Cancer, Breast Cancer Survivor, Ovarian Cancer Survivor, Pancreatic Cancer Survivor, Melanoma Cancer Survivor
INTERVAL: INTense Exercise foR surVivAL in Men With Metastatic Prostate Cancer
Clinicaltrials.gov identifier:
NCT02730338
Quality of Life:
Prostate Cancer Survivor
RADCOMP: A Study at the Heart of Breast Cancer Treatment
Clinicaltrials.gov identifier:
NCT02603341
Treatment:
Breast
IMPRES - Improving Memory after RRSO
Clinicaltrials.gov identifier:
NCT03187353
Quality of Life:
High Risk But No Cancer, Breast Cancer Survivor, Ovarian Cancer Survivor
.jpeg?h=300&w=400&fit=contain)
Serum Folate in Patients Treated with Olaparib
Clinicaltrials.gov identifier:
NCT04024254
Treatment:
Breast, Ovarian
Sponsored By:
